Research Paper Volume 13, Issue 5 pp 7020—7034
The efficiency and safety of high-dose vitamin C in patients with COVID-19: a retrospective cohort study
Figure 2. Survival by severe and critical disease (A) and age > 60 years old (B). Survival is stratified by disease severity at baseline and by age. (A) In patients with severe or critical disease, the risk of mortality was lower for patients with high-dose vitamin C than that with standard therapy (HR= 9.91, 95% CI, 1.82-54.00); (B) In patients with age > 60, the risk of mortality was lower for patients with high-dose vitamin C than that with standard therapy (HR=7.98, 95% CI, 1.24-51.22). VitC: vitamin C.